The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Vertex Pharmaceuticals and Achillion Pharmaceuticals

News provided by

Dec 31, 2014, 09:30 ET

CHICAGO, Dec. 31, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead Sciences Inc. (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), Vertex Pharmaceuticals Inc. (Nasdaq:VRTX-Free Report) and Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday's Analyst Blog:

3 Biotechs That Soared Past Gilead in 2014

It has been an eventful year for Gilead Sciences Inc. (Nasdaq:GILD-Free Report), a big name in the biotech sector. Gilead, which soared 100.11% in 2013, is up only 29.37% year-to-date (YTD). Throughout 2014, the company was in the news mainly due to its hepatitis C virus (HCV) treatment, Sovaldi, which was approved by the FDA in Dec 2013. While the drug's approval was a welcome relief for HCV patients who had postponed treatment as they awaited better and safer treatment options, Gilead's pricing of the drug came under heavy criticism.

Sovaldi Pricing Issues

In fact, in late Mar 2014, the pricing issue came to the forefront with U.S. lawmakers questioning Gilead about the same -- the $84k price tag for a 12-week treatment period was considered too expensive.

This shook the entire biotech sector and resulted in a selloff that was fueled further by speculation about a biotech bubble. Rumors that other drugs would also come under the same pricing scrutiny started doing the rounds.

Despite pricing concerns, Sovaldi showed no signs of slowing down with the product bringing in sales of $8.6 billion in the first nine months of 2014. Gilead had more good news in store -- another HCV treatment, Harvoni, with huge commercial potential gained approval this year.

A Look at Some Biotech Stocks That Fared Better than Gilead

Here is a look at a few biotech stocks with a link to the HCV market that fared better than Gilead in 2014.

North Chicago, IL-based AbbVie (NYSE:ABBV-Free Report) fared better than Gilead with a YTD return of 33.35%. AbbVie, a Zacks Rank #2 stock (Buy), is a strong contender in the HCV market with its highly-awaited Viekira Pak gaining FDA approval recently. Earnings estimates are on the rise and Viekira Pak is being viewed as a blockbuster. Express Scripts' backing should help AbbVie pick up share in the U.S. market.

Boston, MA-based Vertex Pharmaceuticals Inc. (Nasdaq:VRTX-Free Report) is another stock which did well this year and is worth keeping an eye on in 2015. Vertex was once a force to reckon with in the HCV market. Incivek, approved by the FDA in 2011, changed the treatment paradigm in the HCV market and brought in billion dollar sales for the company. However, with newer treatments like Sovaldi entering the HCV market, Vertex saw a sharp decline in HCV sales and decided to exit the market.

Did this decision pay off? It has definitely been a good year for Vertex. The company shifted its focus entirely to its cystic fibrosis (CF) portfolio and flagship product, Kalydeco, has blockbuster potential.

This Zacks Rank #3 (Hold) stock has delivered a YTD return of 62.25% and has multiple catalysts stored for 2015 in the form of Kalydeco's label expansion, launch in additional territories and potential approval of the Kalydeco-lumacaftor combination.

Meanwhile, it's been an exceptionally good year for New Haven, CT-based Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report). While the company is definitely not in the same league as Gilead, it deserves a place in this list. Often touted as a takeover candidate, Achillion has delivered a YTD return of 283.64% and has been consistently in the news thanks to positive updates on its HCV pipeline. This Zacks Rank #2 company is a stock to keep an eye on in 2015 as it continues to provide updates on its experimental HCV treatments.

HCV to Remain in Focus

Will AbbVie change the competitive scenario in the HCV market now that its cocktail treatment has gained approval and is also being supported by Express Scripts? What will be the impact on Harvoni and Sovaldi sales? Will more new HCV treatments enter the market in 2015? Will the biotech sector face pricing pressure for other highly-priced drugs?

These are the questions that have surfaced with the AbbVie -- Express Scripts deal and will keep the HCV market and companies like Gilead, AbbVie and Achillion in focus in 2015.

Be among the first to see Zacks Top 10 Stocks for 2015, a portfolio that consists of our Best-of-the-Best fundamentally sound long-term picks designed to perform in any type of market. Get in before the stocks are released on Jan 2 by clicking here.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on GILD - FREE
Get the full Report on ABBV - FREE
Get the full Report on VRTX - FREE
Get the full Report on ACHN - FREE

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-zacks-analyst-blog-highlights-gilead-sciences-abbvie-vertex-pharmaceuticals-and-achillion-pharmaceuticals-300014797.html

SOURCE Zacks Investment Research, Inc.